



Dry Powder Inhaler

ISO 13485:2016

Certificate Number: MD-205022122903



Company Name: CanDapi Ltd.

Email: amnon@candapi.net

Phone: +972-52-3087728

HQ: Yeruham, Israel

Website: www.candapi.net

LinkedIn: CanDapi

Industry: Medical device

Sector: Dry Powder Inhalers

Founded: 2022

Funding up to date: \$900K

Next round: \$1.7M



Revolutionary Dry Powder Inhaler – DPI>90% Lung Particles

Company Description

CanDapi develops and produces a new type of innovative single dose for multi-use Dry Powder Inhaler (DPI) device for delivering medications including cannabinoids (CBD/THC) to the lungs in the form of a dry powder, for various treatments.

Problems We Solve

- Current inhalation types of cannabis delivery treatments are unsafe and harmful to users, due to side effects of the inhaling devices (cigarettes, vapes).
- New high-cost medications including biotherapeutics require a solution for an efficient delivery method.
- Current inhalers used to treat lung diseases show very low efficiency of drug delivery to the lungs for patients of all ages. Over 50% of the medication is wasted

CanDapi Solution

- A new method of medicine inhalation, developed by CanDapi, in the form of totally new patented inhalers.
- The new CanDapi DPI is operated using high-frequency vibrations activated by inhaling. This method is an exceptional and innovative drug delivery mechanism with tested results of over 85% efficiency by Kiel university and an efficiency of cannabis powder of 92% as tested by Cannasoul (The Technion company).
- The most safe and effective solution suitable for the efficient delivery of cannabis powder ingredients.
- The most effective solution for new drugs including biotherapeutics.
- The perfect solution for more effective treatment for lung diseases as asthma and COPD (Chronic Obstructive Pulmonary Disease).

Addressable Market

- Medical & Wellness Cannabis - \$30Bn
- New Drugs Including Biotherapeutics - \$43Bn
- Lung Diseases - \$54Bn

Traction

- Grants and investments- \$650K (IIA), \$350K others
- IP- US PCT and new Provisional Patent Application
- International collaboration is already in process
- Standards and Certifications- ISO13485, GMP
- Negotiation with two international companies

Founders & Team

Amnon Kritzman Kadron, CEO & founder: Engineer (M.Sc.) Technion, Israel. An entrepreneur, inventor, and manager of medical devices & biotechnology companies. Amnon is the co-inventor of the innovative CanDapi inhaler.

Guy Arfi, CTO: B.Sc.: Mechanical engineer, Ben Gurion University, Israel. An R&D engineer expert in the design of plastic products, planning and manufacturing. Guy is the co-inventor of the innovative CanDapi inhaler.

Capital Structure – Top Shareholders

CanNegev Incubator (46%)
 Amnon Kritzman Kadron (25.3%)
 Cannasoul Analytics (16.9%)
 IMC (2.8%)



Milestones:

Q4 2022

Complete R&D
 ISO-13485
 USA Prov. Patent

Q3 2023

Assembly of 1K units

Q2 2024

End of new product R&D

Q3 2024

Pre-seed fund raising

Starting sales for

cannabis wellness DPI



Q2 2022

Company founded

Q2 2023

Assembly line installed

Q4 2023

PCT patent app.

End of pre-clinical

Q4 2024

End of clinical studies

Q4 2025

FDA 510K/CE approval
 Starting sales of
 medical devices

Fundraising requirement:

\$1.7M

Target closing date:

Q1 2024

Use of main proceeds:

54% - R&D and Clinical Studies

21% - Business Development & Marketing

14% - Manufacturing

11% - Operational Cost